Millendo Raises $62m, Licenses AstraZeneca Drug
This article was originally published in Scrip
Executive Summary
Millendo Therapeutics raised $62m in a Series B round led by New Enterprise Associates and the endocrine disorder-focused biotech firm licensed a polycystic ovary syndrome (PCOS) drug candidate from AstraZeneca PLC in a deal that will widen the company's focus.
You may also be interested in...
Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
GSK Spin-Out NeRRe Raises £23m For NK Antagonists
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.